Health technology assessment body NICE today published the reasons why it decided in September that Novartis’s CAR T-cell therapy Kymriah (tisagenlecleucel) should not be routinely used by England’s National Health Service for young people with leukemia but should instead be provided via the Cancer Drugs Fund.
NICE Explains Its UK Funding Recommendation For Kymriah
The final appraisal document published today by the health technology assessment body NICE provides more insight into the health technology assessment body’s recent recommendation on Kymriah’s use in young people with leukemia.
